Financials

  • Market Capitalization 1.01 B
  • Employee 6 500
  • Founded 1979
  • CEO Douglas C Bryant
  • Website www.quidelortho.com
  • Headquarter California, United States
  • FIGI BBG017TGV7M2
  • Industry Medical Devices
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.76
Price to sales ratio
0.73

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2395
IRMD
iRadimed Corporation - Common Stock
87.07 USD+0.08%-1.21%-7.62%+21.56%1.11 B USD
2400
LMRI
Lumexa Imaging Holdings, Inc. - Common Stock
11.51 USD-1.88%-7.10%+10.67%-38.28%1.11 B USD
2494
INMD
InMode Ltd. - Ordinary Shares
14.85 USD+0.07%-1.59%-1.98%-3.32%940.88 M USD
2504
CBLL
CeriBell, Inc. - Common Stock
23.73 USD+1.54%-0.92%+33.24%+83.67%910.71 M USD

Frequently asked questions about QuidelOrtho Corporation Common Stock

What is the QuidelOrtho Corporation Common Stock stock price today?

The current price of QuidelOrtho Corporation Common Stock (QDEL) is 14.74. Over the past 24 hours, the stock has changed by -3.79%. Follow the QDEL chart for real-time price dynamics.

What is the stock ticker of QuidelOrtho Corporation Common Stock?

QuidelOrtho Corporation Common Stock trades under the ticker QDEL. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is QuidelOrtho Corporation Common Stock stock going up?

QDEL has changed by 0.00% over the last week, -10.67% over the last month, and -51.69% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of QuidelOrtho Corporation Common Stock?

QuidelOrtho Corporation Common Stock currently has a market capitalization of 1.01 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were QuidelOrtho Corporation Common Stock earnings last quarter?

Last quarter, QuidelOrtho Corporation Common Stock reported earnings of -1.95 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was QuidelOrtho Corporation Common Stock revenue for the last quarter?

QuidelOrtho Corporation Common Stock reported quarterly revenue of 723.6 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was QuidelOrtho Corporation Common Stock net income for the last quarter?

QuidelOrtho Corporation Common Stock reported net income of -130.7 M for the last quarter. The previous quarter showed -733 M, which means net income changed by +82.17%.

How many employees does QuidelOrtho Corporation Common Stock have?

As of the latest available data, QuidelOrtho Corporation Common Stock has 6 500 employees. Workforce size can provide additional context about the company's scale and operations.

What is QuidelOrtho Corporation Common Stock EBITDA?

QuidelOrtho Corporation Common Stock EBITDA is -769.1 M, and its EBITDA margin is -106.29%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy QuidelOrtho Corporation Common Stock stock?

You can buy QuidelOrtho Corporation Common Stock (QDEL) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in QuidelOrtho Corporation Common Stock stock?

Investing in QuidelOrtho Corporation Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the QDEL chart and related analysis on metatrader.com as part of your research.

QuidelOrtho Corporation - Common Stock

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.

News